Ampyrone (Standard)

Ampyrone (4-Aminophenazone) (Standard) is the analytical standard of Ampyrone (HY-B1398) . This product is intended for research and analytical applications. Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy[1][2][3].

Product Specifications

CAS Number

[83-07-8]

Product Name Alternative

4-Aminophenazone (Standard)

UNSPSC

12352005

Hazard Statement

H302

Target

COX; Drug Metabolite; Reference Standards

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; Others

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Purity

99.23

Smiles

O=C1C(N)=C(C)N(C)N1C2=CC=CC=C2

Molecular Formula

C11H13N3O

Molecular Weight

203.24

Precautions

H302

References & Citations

[1]Berno CR, et al. 4-Aminoantipyrine reduces toxic and genotoxic effects of doxorubicin, cisplatin, and cyclophosphamide in male mice. Mutat Res Genet Toxicol Environ Mutagen. 2016 Jul;805:19-24.|[2]Keck CHC, et al. Color-neutral and reversible tissue transparency enables longitudinal deep-tissue imaging in live mice. bioRxiv [Preprint]. 2025 Feb 27:2025.02.20.639185.|[3]Kalaskar, et al. Evaluation of ampyrone (4-aminoantipyrine), an activator of the intra-melanosomal domain of human tyrosinase, as a potential therapeutic agent for oculocutaneous albinism type 1B. Investigative Ophthalmology & Visual Science 63.7 (2022) : 676-F0130.